Genetic testing for the long QT syndrome: who and why? Insights for clinical management by Schwartz, Peter J.
Genetic testing for the long 
QT syndrome: who and why?
Insights for clinical management
LQTS(7-9) has represented a major revolution not only from a 
conceptual point of view but also from a practical one. Initially, the 
general attitude was that “genetics” were a lab curiosity that could 
interest researchers but not the clinical cardiologist who had to 
take the day-by-day decisions on how to best manage his/her 
patients. It is no longer so. Molecular screening for the diagnosis of 
LQTS has become an essential tool for clinical management and 
can no longer be ignored by clinical cardiologists. Indeed, during 
2011 two different documents were produced aimed at providing 
guidelines for genetic screening for a variety of diseases associated 
with sudden death.(10,11)
I will not discuss these documents and I will, instead, present my 
personal views – based on over 40 years of clinical and research 
experience with LQTS – on the role of genetic testing for this 
disease. I will discuss why genetic testing should be performed, who 
should undergo genetic testing, and the consequences for not 
performing it.
WHY IS GENETIC SCREENING REQUIRED?
For diagnostic purposes
Genetic testing should be performed whenever there is a strong or 
reasonable suspicion that the patient is affected by LQTS. As a 
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COMMENTARY
The long QT syndrome (LQTS), a major cause of sudden death in 
the young, is a well-known genetic disorder with prevalence among 
Caucasians of approximately 1 in 2 000 live births.(1) It is charac-
terised by QT interval prolongation on the ECG and by syncopal 
episodes caused by a ventricular tachycardia called Torsades-de-
Pointes which often deteriorates into ventricular fibrillation.(2,3) 
Most of these arrhythmic episodes occur during physical or 
emotional stress, but they may also occur at rest.(4) Thirteen LQTS 
genes have been identified so far(3) but more than 90% of cases 
are due to mutations on 3 genes encoding the IKs (LQT1) and IKr 
(LQT2) currents and the cardiac sodium current (LQT3). Sympto-
matic patients who are not treated properly(3) have a very high risk 
of dying suddenly whereas for those treated with anti-adrenergic 
interventions, either ß-blockers or left cardiac sympathetic dener-
vation (LCSD),(5,6) mortality has been dramatically reduced from 
almost 60% within 10 years from the first cardiac event to 1%.(3)
The identification in 1995-1996 of the first 3 major genes for 
This article deals with a specifi c issue of growing importance 
for cardiologists or internists who happen to have to take 
care of a patient affected by the congenital long QT syndrome 
(LQTS), namely when to consider to request a genetic test. 
The focus is on who are the patients for whom genetic 
screening should be requested and why. One often ignored 
issue is also discussed, the potentially very serious con-
sequences – for the patient and also for the doctor – of 
omitting genetic screening. The bottom line is that genetic 
screening for LQTS can no longer be regarded as a research 
tool but is an integral part of current medical management 



















matter of fact, this is not always so obvious. It is for this reason that 
in 1993(12) we proposed a set of diagnostic criteria which became 
subsequently known as the “Schwartz criteria”. These criteria were 
subsequently updated in 2006(13) and 2011(14) (see Table 1). They 
provide a quantitative score so that, for example, from 3.5 points 
upward the likelihood of the patient to be affected by LQTS is high. 
Besides its immediate use in the office for a first clinical diagnostic 
assessment, the Schwartz score should be used to select patients 
for genetic screening and its results will then be used to identify, 
by cascade screening, the “silent” mutation carriers (see below). It 
is important to keep in mind that in patients with a firm diagnosis of 
LQTS the success of genotyping in identifying the disease-causing 
mutation exceeds 80%.
For gene-specifi c clinical management 
Gene-specific triggers for life-threatening cardiac events have been 
identified.(4) For LQT1 patients over 90% of these events occur 
during conditions of sympathetic activation, physical or emotional 
stress. Swimming is especially dangerous for these patients and 99% 
of the LQTS patients with syncope while swimming are LQT1. 
LQT2 patients are exquisitely sensitive to sudden noises, such an 
alarm clock going off or a telephone ring and 80% of the LQTS 
patients with noise-related syncope are LQT2. LQT3 patients most 
commonly die while at rest or during sleep. On the other hand, 
because of their normal IKs current which allows proper QT 
shortening during heart rate increases,(3) LQT2 and LQT3 patients 
are at very low risk during exercise. After successful genotyping it 
becomes possible to make gene-specific recommendations to 
avoid risk. As an example, we discourage the use of alarm clocks 
and telephones in the bedrooms of LQT2 patients.(3) Also, if a 
LQTS patient is found to be an LQT3 patient then we test the 
sodium channel blocker mexiletine which, in many of these patients, 
can markedly shorten the QT interval and become a useful addition 
to beta-blocker therapy.(15)
Genetic testing and ICD implants
The misconception that LQT3 patients are not well protected by 
ß-blockers has led to a sort of knee-jerk reaction by which the 
simple notification that genetic testing has identified the patient as 
a LQT3 case prompts an almost immediate ICD implant.(16) This 
has resulted in a large number of LQT3 patients being implanted 
with an ICD despite the fact that they are completely asympto-
matic.(17) The reality is quite different. It is true that LQT3 patients 
with syncope and cardiac arrest in the first year of life represent a 
special subset at very high risk and poorly responding to therapy, 
but most LQT3 patients without cardiac events during the first 
year of life, do very well on ß-blockers or with LCSD without any 
need for an ICD.(18) Our initial observation(18) is fully supported by 
an upcoming study on over 400 LQT3 points.(19)
The genetic results also help to stratify risk, which differs according 
to genotype, gender, and QT length.(20) Furthermore, the intra-
genic location of the mutations, their different types and functional 
effect are important contributors to outcome.(21,22) The situation is 
TABLE 1:  1993-2011 LQTS diagnostic criteria
#   In the absence of medications or disorders known to affect these electrocardiographic 
features
*  QTc calculated by Bazett's formula where QTc = QT/√RR
** Mutually exclusive
†  Resting heart rate below the 2nd percentile for age
‡  The same family member cannot be counted in A and B
    Points
Electrocardiographic fi ndings# 
A QTc* ≥480ms  3
  460 - 479ms  2
  450 - 459 (male) ms 1
B QTc* 4th minute of recovery from exercise stress test ≥480ms 1
C Torsades-de-Pointes**   2
D T-wave alternans   1
E Notched T-wave in 3 leads   1
F Low heart rate for age†   0.5
Clinical history 
A Syncope** With stress  2
  Without stress  1
B Congenital deafness   0.5
Family history 
A Family members with defi nite LQTS‡  1
B Unexplained sudden cardiac death below age 30 among  0.5
 immediate family members‡
Score
≤1 point low probability of LQTS
1.5 to 3 points intermediate probability of LQTS
≥5 points high probability
From reference 3
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becoming intriguingly more complex as we have shown that we 
are moving toward mutation-specific risk stratification.(23) Indeed, in 
the South African founder population that we have been exten-
sively investigating with our partner Professor Paul Brink,(23-27) we 
have provided the unexpected evidence that the clinical severity 
of this mutation (KCNQ1-A341V) which causes LQT1 is strikingly 
greater than that of other LQT1 mutations. Furthermore, in the 
same South African population we have found that the presence 
of relatively common polymorphisms on the NOS1AP gene can 
actually double the already high risk for sudden death in the patients 
carriers of the A341V mutation.(28) The practical implication is that 
whenever genetic testing identifies particularly malignant mutations 
we can modify our management in the sense of a more aggressive 
strategy in order to better protect our patients.
Genetic testing and identifi cation of “silent” mutation carriers
In 1980, against current wisdom, I made the highly controversial 
suggestion that the spectrum of LQTS might have been larger than 
previously suspected and might have included individuals with a 
normal QT interval on the surface ECG.(29) Within 20 years this 
concept was vindicated,(30,31) and the evidence of low penetrance in 
LQTS was provided.(31) The quantification of the phenomenon was 
provided in 2003(20) when we showed that 37% of LQT1 patients, 
19% of LQT2, and 10% of LQT3 patients actually had a normal QT 
interval. Thus, these large numbers of individuals who apparently 
are not affected by LQTS actually are the “silent” mutation-carriers. 
The huge clinical implication is that these individuals, who are at 
relatively low risk spontaneously, may become at very high risk for 
Torsades-de-Pointes ventricular tachycardia and sudden death if 
they are treated with one of the zillions drugs which have an IKr 
blocking activity and which are commonly used for a variety of 
benign conditions. Once we learn about the mutation of our 
patient, then it becomes easy, inexpensive, and quite rapid, to 
screen his/her entire family for that specific mutation. This opera-
tion, referred to as “cascade screening”,(32,33) is one of the major 
benefits of genetic testing because it allows to identify mutation-
carriers and to protect them from life-threatening arrhythmias by 
insuring that they are never treated with dangerous drugs. Also, 
and equally important, cascade screening allows the identification in 
the enlarged families of other still asymptomatic but fully affected 
patients who can be rapidly placed under proper therapy. A final 
very important point is that cascade screening, by demonstrating 
the absence of the culprit mutation, allows us to reassure the non-
carriers who, by living in families with recurrent sudden deaths, 
often and understandably have major fears and are under significant 
psychological stress.
WHO SHOULD DO GENETIC SCREENING?
Clearly everyone with a definite clinical diagnosis of LQTS should 
undergo genetic screening. The same is true for individuals with a 
Schwartz score >3 points, independently from presence or absence 
of cardiac symptoms.
 ■ Selected survivors of out-of-hospital cardiac arrest, specifically 
those who in the days following the aborted cardiac arrest have 
a QT interval prolongation and those who had their episode in 
conjunction with specific triggers,(4) as discussed above.
 ■ One month old infants with a QTc >470ms and at least 2 
abnormal measurements. The rationale for this statement 
comes from the larger prospective study of neonatal electro-
cardiography ever performed and is based on over 44 000 
newborns.(1) That study, besides providing the first data-based 
prevalence of LQTS, showed that 43% of infants with a QTc 
>470ms in the first month of life were carriers of LQTS-
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FIGURE 1:   All family members of a patient in whom a long QT 






























causing mutations. Importantly, it also demonstrated that 90% 
of infants with a QTc >460ms in the first month of life and 
who had the same QTc values at one year of life were carriers 
of LQTS-causing mutations. Given the clearly established rela-
tionship between LQTS and the risk of Sudden Infant Death 
Syndrome (SIDS),(34-38) the possibility of an early identification 
and early treatment of those apparently healthy infants who 
nonetheless may be at risk for early death represents an 
important step to prevent avoidable tragedies.(39)
 ■ By the same token all victims of sudden death below age 30 
and all SIDS victims should undergo genetic testing. The Mayo 
Clinic group has shown a percentage close to 30% of disease-
causing mutations among young victims of sudden death.(40) 
Thus, genetic testing on post-mortem tissue samples can not 
only lead to find the cause of the lethal event but also to the 
diagnosis of affected family members.(41)
CONSEQUENCES OF OMITTING GENETIC 
SCREENING
Before the identification of the LQTS genes, a normal QT interval 
in the family members was sufficient to allow the physicians to 
exclude the presence of LQTS. This is no longer possible. Figure 1 
is a cartoon depicting a fairly common situation that may present 
itself in our medical rooms. Imagine a family coming for diagnosis 
and advice after their young boy has fainted at school. You perform 
an ECG and observe a clear cut QT prolongation (QTc 500ms): 
The father has normal QTc while the always asymptomatic mother 
has a modest QT interval prolongation. You turn to the parents 
and say that the boy is affected by LQTS, almost certainly inherited 
by the mother, and that you will immediately start him with 
ß-blockers at full dose. And this is all good. Then, the parents ask 
you: “What about our girl”? Her QTc is 430ms, within normal 
range. Twenty years ago you would have said: “Nothing to worry, 
she does not have it”. Not now. 
Nowadays, with the evidence that 20-30% of LQTS patients may 
be silent mutation carriers and have a normal QT interval we 
cannot say that anymore. Imagine again that the little girl is indeed 
a silent mutation carrier and that you have discounted her possi-
bility of being affected just based on the normal ECG; few months 
later she may have an acute tonsillitis and her good pediatrician 
treats her with erythromycin, which is a potent IKr blocker, and 5 
days later she dies suddenly because of drug-induced QT prolon-
gation and Torsades-de-Pointes. Cruel fate? Destiny? No, it is your 
fault. You, or anyone of us, have no right in assuming that a normal 
QT interval in a family member of a LQTS patient excludes the 
disease. And everything depends on genotyping the proband, the 
first affected member of the family who comes to medical attention. 
If genotyping is negative, nothing else can be done; but if it is 
positive then cascade screening can take place immediately.
The growing knowledge about LQTS is also complicating the lives 
of medical doctors and previously unsuspected reasons for medico-
legal considerations are now on the table.(42) Please, remember: 
The physician who decided not to genotype his/her patient has also 
willfully chosen to ignore the possibility that some family members 
are silent mutation carriers. This is no longer justifiable. If genetic 
testing is not available, then the responsible physician should at 
least alert the family to the existence of this potential danger and it 
will be up to the family to decide the next move.
CONCLUSION
The genetic era has catapulted all of us practicing cardiologists into 
a new dimension. We can no longer ignore the implications of the 
fact that it is now possible to identify the specific mutations 
responsible for LQTS. Molecular screening and genetic testing do 
no more represent research tools, they have become a fully fledged 
part of what has to be routine clinical management of patients 
affected by the long QT syndrome. 
Conflict of interest: none declared.
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